Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemiralisib in Acute Exacerbation of COPD
NCT02522299Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of nemiralisib in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoint: Change in Messenger Ribonucleic Acid (mRNA) Transcriptome in Induced Sputum at Day 84. Started Nov 2015; status: completed.
02
Drugs
nemiralisib
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02522299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02522299.